申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0198633A2
公开(公告)日:1986-10-22
The present invention provides compounds of formula (1) :-
and their pharmaceutically acceptable salts.
In formula (1)
R1 and R2 are the same or different and are hydrogen, C1-6alkyl, C1-6 alkoxy or halogen;
R3 is C1-6salkyl or optionally substituted phenyl or optionally substituted pyridyl, where the optional substituents are one or more C1-6alkyl,
C1-6alkoxy, or hydroxy or halogen atoms;
a is from 2 to 4
R4 is (CH2)bR5 where b is 1-6 and
R5 is phenyl optionally substituted by one or more C1-6 alkyl, C1-6alkoxy, hydroxy, carboxy (or an ester thereof) or sulphonamido groups or halogen atoms; pyridyl optionally substituted by one or more C1. 6alkyl, C1-6alkoxy or hydroxy groups or halogen atoms; or N-oxo-pryidyl optionally substituted by C1-6alkyl; and
r is 1 or 2.
The compounds are useful as histamine H1- antagonists.
本发明提供了式 (1) :- 的化合物及其药学上可接受的盐类。
及其药学上可接受的盐类。
在式 (1) 中
R1 和 R2 相同或不同,并且是氢、C1-6 烷基、C1-6 烷氧基或卤素;
R3 是 C1-6 烷基或任选取代的苯基或任选取代的吡啶基,其中任选取代基是一个或多个 C1-6 烷基、
C1-6烷氧基、羟基或卤素原子;
a 是 2 至 4
R4 是 (CH2)bR5,其中 b 是 1-6 和
R5 是任选被一个或多个 C1-6 烷基、C1-6烷氧基、羟基、羧基(或其酯)或磺酰胺基团或卤素原子取代的苯基;R6 是任选被一个或多个 C1-6 烷基、C1-6烷氧基、羟基、羧基(或其酯)或磺酰胺基团或卤素原子取代的吡啶基;R7 是任选被一个或多个 C1.6烷基、C1-6烷氧基或羟基或卤素原子取代的吡啶基;或任选被 C1-6 烷基取代的 N-氧代丙烯酰基;以及
r 为 1 或 2。
这些化合物可用作组胺 H1 拮抗剂。